<DOC>
	<DOCNO>NCT01037205</DOCNO>
	<brief_summary>This protocol seek enroll adult otherwise healthy subject present influenza-like illness ( ILI ) . Subjects enter study base list inclusion/exclusion criterion , include positive diagnostic test influenza virus ( IFV ) .</brief_summary>
	<brief_title>Randomized , Double-blind , Placebo Controlled Phase II Study Examine Effects DAS181 Healthy Adult Subjects With Laboratory Confirmed Influenza</brief_title>
	<detailed_description>This protocol seek enroll adult otherwise healthy subject present influenza-like illness ( ILI ) . Subjects enter study base list inclusion/exclusion criterion , include positive diagnostic test influenza virus ( IFV ) . Based upon Rapid Diagnostic Test IFV , subject randomize one three group : single dose DAS181 10 mg group , multiple dose DAS181 10 mg , 10 mg , 10 mg dose group placebo group . The full analysis set include subject confirm influenza document Rapid Diagnostic Testing . The set use activity analysis include randomize subject baseline treatment data . Study staff may visit subject outside clinic . Per protocol , safety analysis set describe Statistical Methods . Peripheral venous blood sample pharmacokinetic ( PK ) immunogenic analysis DAS181 obtain 10 subject enrol study arm .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>1 . Male female subject generally good health opinion investigator determine vital sign , medical history , target physical exam base medical history . 2 . Subjects must able verbalize understanding consent form , provide write informed consent verbalize willingness complete study procedure . 3 . Be 18 70 year age ( inclusive ) . 4 . Subjects must weigh least 55 kg must Body Mass Index ( BMI ) great 35.99 5 . Febrile , oral temperature &gt; 100°F ( 37.8°C ) one following : Respiratory symptom ( cough , sore throat , nasal symptom ) Constitutional symptom ( headache , myalgia , sweat/chills , prostration ) 6 . Positive rapid antigen test ( RAT ) influenza perform use FDACleared CLIAWaived commercially available rapid antigen test . A subject may enrol follow positive RAT manufacturer . Test may conduct primary care physician prior study enrollment documentation positive RAT provide ( documentation may consist subject medical record must include subject documentation ) . A subject negative RAT result may still enroll sponsor investigator agree know influenza outbreak circulate community . Blood pressure within normal limit ( systolic 90150 mmHg ; diastolic 5095 mmHg ) heart rate 45 140 beat per minute . 7 . Blood pressure within normal limit ( systolic 90150 mmHg ; diastolic 5095 mmHg ) heart rate 45 140 beat per minute . 8 . Onset illness 48 hour prior diagnosis . Note : Time onset illness define either ( 1 ) time temperature first measure elevate ( least one degree ( °C ) elevation temperature ) , OR ( 2 ) time subject experienced presence least one respiratory symptom presence least one constitutional symptom . 9 . Female subject must postmenopausal ( one year great without menses ) , surgically incapable childbearing , practice abstinence practice two effective method birth control . Acceptable method may include intrauterine device , spermicide , barrier hormonal contraception . A female subject must agree practice acceptable method birth control study period 12 week study terminates . All female subject regardless menopausal status surgical history must negative urine pregnancy test ( urine betahuman chorionic gonadotropin [ hCG ] ) screen visit . The urine pregnancy test must sensitive least 50 mU/mL betahCG . 10 . Male subject must agree use medically accept form contraception time enrollment 12 week study termination . Exclusion : 1 . Have receive investigational drug vaccine within 8 week prior study drug dosing . 2 . Have serious adverse reaction hypersensitivity drug . 3 . Have receive blood product within 6 month study enrollment . 4 . Have concurrent cystic fibrosis , emphysema previous episode anaphylaxis . 5 . Have sicklecell disease . 6 . Allergy history allergy milk lactose . 7 . Any history congenital acquire bleeding abnormality . 8 . Existence surgical , medical , laboratory condition , judgment clinical investigator , might interfere safety , distribution , metabolism excretion drug . 9 . Use antiviral influenza medication within 10 day prior screen ( subject prohibit take antiviral influenza medication course trial ) . 10 . Current clinical evidence recognize suspect uncontrolled noninfluenza infectious illness onset prior screen . 11 . Known hypersensitivity DAS181 . 12 . Women pregnant ( urine pregnancy test ) , attempt become pregnant , breastfeed . 13 . Uncontrolled seizure disorder history seizure activity within 12 month prior study participation . 14 . Any significant finding subject 's medical history physical examination , opinion investigator , would affect subject safety compliance dose schedule . 15 . Documented infection IFV past 2 week . 16 . Subjects previous current history asthma COPD require acute chronic medication . 17 . Subjects acute diagnosis chronic medical condition within last 3 month . 18 . Subjects chronic medical condition initiate change dose regimen prescription medication chronic medical condition within last 3 month ( change chronic medication 28 day enrollment period capture source documentation concomitant medication ) . 19 . Subjects previous current history follow systemic disorder : immunological disorder , HBV , HCV cirrhosis , transplant recipient , HIV infection , immunosuppressive illness . 20 . Subjects cancer history hematologic malignancy . Cancer define active neoplastic disease exclude noninvasive basal cell carcinoma . 21 . Subjects schedule surgery within 30 day initiation study . 22 . Subjects donate lose 500 mL blood two month prior screen . 23 . Psychiatric cognitive illness recreational drug/alcohol use , opinion principal investigator , would affect subject safety and/or compliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>